Investor Presentaiton
USA
43
21
~10-12
39
Approvals
(1 each of Final &
Tentative in
H1 FY 2023)
Under
Approval
Filing Target
(3 filed in
H1 FY 2023)
Products on
Shelf
■ Price erosion, no new approvals & launches impacted H1.
■ Dahej USFDA inspection completed successfully.
300
Export Sales - Q2 (Consolidated)
Asia Branded
(Rs. cr.)
31%
300
251
Total Exports
(Rs. Cr.)
191
200
1%
700
1001
611
615
600
500
400
300
200
100
Q2 FY22 ■Q2 FY23
Africa Branded
(Rs. cr.)
300
(8%)
USA Generics
(Rs. Cr.)
(5%)
300
Africa Institution
(Rs. cr.)
194
185
(50%)
200
200
200
159
146
100
■Q2 FY22
Q2 FY23
Sales Q2 FY22
100
Q2 FY22
■Q2 FY23
Sales Q2 FY23
USA
32%
USA
30%
Africa Institution
Africa Institution
11%
Asia Branded
Africa Branded
24%
31%
Africa Branded
25%
Q2 FY22 ■Q2 FY23
Asia Branded
41%
100
66
33
Q2 FY22
Q2 FY23
ajanta
17 of 37
ajanta
18 of 37
9View entire presentation